Biotechnology Thought-Leader David Perryman Presents at Acclaimed TED2007 Conference.

Stem Cell Innovations' Counsel to Discuss Innovative PluriCell[TM] Technology

HOUSTON -- Stem Cell Innovations, Inc. (OTCB: SCLL) today announced that David G. Perryman, J.D., noted author and lecturer on biotechnology, founder and intellectual property counsel to Stem Cell Innovations (SCI) presents a short talk at TED2007, a four day gathering that provides a forum for extraordinary individuals from science, technology, business, and the arts. Mr. Perryman will discuss SCI's PluriCell[TM] programs and how that technology will shape the future of biotechnology research. The meeting will be held March 7-10 at the Monterey Conference Center in Monterey, California.

SCI's core technology focuses on developing, growing, and manipulating human cells in the laboratory using proprietary technology. By growing pure cultures of individual cell types, SCI is developing a broad array of human primary cell models as powerful research tools that can form the basis of therapeutic breakthroughs.

SCI has established several human pluripotent stem cell lines from fetal gonadal tissue using defined conditions. These PluriCell([TM]) lines have been established directly onto tissue culture plastic without the use of feeder layers or conditioned medium. In addition to the PluriCell technology SCI has already established in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox([R]) and PREDICTIVTox(tm).

"We congratulate David on being recognized for his continuing contribution to the biotechnology industry," said James H. Kelly, Ph.D., Chief Executive Officer of SCI. "David has been a major presence in biotechnology for over 20 years and his insights into our technology, including the PluriCell[TM] lines will undoubtedly be a highlight of the TED 2007, 'Icons, Geniuses and Mavericks.' meeting."

About TED2007

Founded in 1984, the TED (Technology, Entertainment, Design) conference is an annual event where leading thinkers and doers gather for inspiration. The first TED included the public unveiling of the Macintosh computer and the Sony compact disc. Past speakers have included Bill Gates, Frank Gehry, Jane Goodall and Reverend Billy Graham. Speakers at TED2007 will include venture capitalist, John Doerr, athlete, Kareem Abdul-Jabbar, former U.S. president, Bill Clinton and musician, Paul Simon. For more information visit www.TED.com.

About Stem Cell Innovations, Inc.

Stem Cell Innovation (SCI) is a cell biology company with offices in Scotch Plains, NJ, and facilities in Houston, TX, and Leiden, the Netherlands. SCI's proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy. The company is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company's currently marketed ACTIVTox([R]) human liver cell-based toxicology offerings.

www.stemcellinnovations.com

ACTIVTox and PluriCells are trademarks of Stem Cell Innovations, Inc.

Forward Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because theses forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more or these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.